Cognition Therapeutics Inc. Files Prospectus for $30 Million Stock Offering to Fund Phase 3 Neurodegenerative Drug Development
Reuters
Sep 03
Cognition <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Files Prospectus for $30 Million Stock Offering to Fund Phase 3 Neurodegenerative Drug Development
Cognition Therapeutics Inc. has filed a prospectus with the U.S. Securities and Exchange Commission (SEC) as part of a registered direct offering of common stock. The company, focused on developing treatments for neurodegenerative disorders, closed the offering of 14,700,000 shares at $2.05 per share, raising approximately $30 million in gross proceeds. This capital is intended to support the Phase 3 development of their drug, zervimesine. Titan Partners Group, a division of American Capital Partners, served as the sole placement agent. The shares were offered under a shelf registration statement that became effective on January 3, 2023. The prospectus is accessible through the SEC's website or by contacting Titan Partners Group directly.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cognition Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9521930-en) on September 02, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.